Brokerages Set Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Target Price at $9.29

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) have been given a consensus recommendation of “Buy” by the eleven analysts that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.29.

Several research firms have recently issued reports on ACHN. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Leerink Swann raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $4.00 to $6.00 in a research report on Thursday, May 18th. Robert W. Baird raised their target price on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, April 24th. Finally, Jefferies Group LLC reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th.

TRADEMARK VIOLATION NOTICE: This article was first posted by [[site]] and is the property of of [[site]]. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at [[permalink]].

Achillion Pharmaceuticals (NASDAQ ACHN) traded down 4.86% during mid-day trading on Monday, hitting $4.11. 1,681,353 shares of the stock were exchanged. The company has a 50-day moving average of $4.48 and a 200-day moving average of $4.13. Achillion Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $9.49. The stock’s market capitalization is $561.93 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. During the same quarter in the prior year, the business posted ($0.13) EPS. On average, equities analysts predict that Achillion Pharmaceuticals will post ($0.64) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Deschutes Portfolio Strategy LLC boosted its position in Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 3,000 shares during the last quarter. Teza Capital Management LLC acquired a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at about $131,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at about $138,000. Highbridge Capital Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at $149,000. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares during the period. 71.27% of the stock is currently owned by institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.